Background. The American College of Surgeons Oncology Group Z0011 trial demonstrated the safety of omitting axillary lymph node dissection (ALND) for women with fewer than three positive sentinel lymph nodes (SLNs) who are undergoing breast-conservation therapy (BCT). Because most of the women were postmenopausal with estrogen receptor (ER) positive cancers, applicability of ALND for younger patients and those with triple-negative (TN) or human epidermal growth factor receptor 2 (HER2) overexpressing (HER2?) tumors remains controversial. Methods. From August 2010 to December 2015, patients undergoing BCT for cT1-2N0 disease and found to have positive SLNs were prospectively followed. Axillary lymph node dissection was indicated for more than two positive SLNs or gross extracapsular extension. Clinicopathologic characteristics, axillary surgery, nodal burden, and outcomes were compared between the high-risk patients (TN, HER2?, or age \50 years) and the remaining patients, termed average risk patients. Results. Among 701 consecutive patients, 242 (35 %) were high risk: 31 (13 %) with TN, 48 (20 %) with HER2?, 130 (54 %) with age less than 50 years, and 33 (14 %) with more than one high-risk feature. The remaining 459 patients (65 %) were average risk. The high-risk patients were younger, had higher-grade tumors (p \ 0.0001), and more often had abnormal nodes imaged (p = 0.02). In this study, SLNB alone was performed for 85 % high-risk versus 82 % average-risk cases (p = 0.39). A median of four versus three SLNs were excised (p = 0.04), and both groups had a median of one positive SLN. Additional positive nodes at ALND were found in 62 % high-risk patients versus 65 % average-risk patients (p = 0.8), with a median of three positive nodes in both groups. During a median follow-up period of 31 months, no patients experienced isolated axillary recurrences. Conclusions. Axillary lymph node dissection was no more likely to be indicated for high-risk patients. For patients undergoing ALND, the nodal burden was similar. For patients otherwise meeting the American College of Surgeons Oncology Group (ACOSOG) Z0011 clinical eligibility criteria, ALND is not indicated on the basis of age or subtype.
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The presence of axillary metastases is an important prognostic factor in invasive breast cancer. The approach to the axilla has evolved significantly in the past decade, with sentinel lymph node biopsy (SLNB) becoming the preferred method for axillary staging. [1] [2] [3] The American College of Surgeons Oncology Group (ACOSOG) Z0011 trial demonstrated no difference in locoregional recurrence (LRR) or overall survival among women with T1-T2 clinically node-negative (cN0) tumors undergoing breastconserving surgery followed by whole-breast radiation therapy (BCT) and systemic therapy when those with fewer than three positive sentinel lymph nodes (SLNs) were managed with SLNB alone compared with SLNB and axillary lymph node dissection (ALND). 4 The After Mapping of the Axilla: Radiotherapy or Surgery? (AMAROS) trial similarly showed noninferiority of SLNB and axillary radiation therapy compared with ALND for patients with fewer than three positive SLNs.
Evidence provided by the ACOSOG Z0011 trial has led to omission of ALND and its associated morbidity for many women. 6 Despite this paradigm shift, the applicability of these results to patients at higher risk for distant metastases, including younger women and those with estrogen receptor-negative (ER-) or human epidermal growth factor receptor 2 (HER2) overexpressing (HER2?) disease has been questioned because most women in the Z0011 trial were postmenopausal and had ER positive (ER?) disease. 4 This study sought to compare the need for ALND ([2 positive SLNs, gross extracapsular extension [ECE]) in high-risk patients (defined as those with triple-negative [TN] or HER2? breast cancers or patients younger than 50 years) with the use of ALND for those lacking these high-risk features in a prospective, consecutive series of cT1-2N0 patients with positive SLNs. Additionally, the residual nodal disease burden was compared between groups in those requiring ALND.
METHODS

Patient Cohort
Beginning in August 2010, consecutive patients with clinical T1-T2 cN0 invasive breast cancer undergoing BCT who were found to have SLN metastases by routine hematoxylin and eosin (H&E) staining at Memorial Sloan Kettering Cancer Center were managed without ALND if metastases were present in one or two SLNs and underwent ALND if three or more positive SLNs or gross ECE was present. Intraoperative frozen section was not used, and ALND was performed as a second separate procedure when indicated. Management of nodes with microscopic ECE was by surgeon preference.
The patients were prospectively entered into a registered database. Those receiving neoadjuvant chemotherapy, those with SLN metastases detected only by immunohistochemistry, and those requiring mastectomy after attempted breast conservation were excluded from the study.
After institutional review board approval, patients treated between August 2010 and December 2015 were identified. Those with TN or HER2? tumors and those younger than 50 years at diagnosis were categorized as high-risk patients, whereas the remainder of the population was termed average-risk patients. Hormone receptor positivity was defined as 1 % or more of cells staining for ER or progesterone receptor. The study defined HER2 positivity as 3? staining by immunohistochemistry or fluorescence in situ hybridization (FISH) amplification with a value greater than 2.
Variables Studied
Standard clinical and pathologic data were collected including patient age, clinical presentation of disease, tumor size, grade, and final tumor and nodal pathologic findings. Rates for administration of systemic therapies were assessed. Outcomes of interest were rates of ALND and number of positive nodes at ALND.
Statistical Analysis
Comparisons between high-and average-risk groups were made using the Chi square test and the two-sample t test. All statistical analyses were performed using SAS 9.2 (SAS Institute, Cary, NC, USA), and p values lower than 0.05 were considered significant.
RESULTS
From August 2010 to December 2015, 701 T1-T2 cN0 patients with positive sentinel nodes were identified. Of these patients, 242 (35 %) were high-risk cases, including 31 TN cases (13 %) and 48 HER2? cases (20 %) among the women 50 years of age or older. Among the patients younger than 50 years, 130 (54 %) had hormone receptorpositive/HER2 negative disease, 11 (5 %) were TN, and 22 (9 %) were HER2?. The remaining 459 cases (65 %) were termed average-risk patients. Table 1 summarizes the clinicopathologic characteristics of both groups. Preoperative axillary imaging was not standard and was performed before referral or by individual physician preference. Abnormal nodes shown by any imaging method were more frequently identified among the high-risk patients (30 % high-risk vs 22 % average-risk patients; p = 0.02), but preoperative nodal biopsy was performed for a similar proportion of patients (7 % highrisk vs 5 % average-risk patients; p = 0.31). Although tumors were more frequently palpable (51 vs 36 %; p \ 0.0001) and appeared larger on imaging (median, 1.9 vs 1.6 cm; p = 0.0001) in the high-risk group, pathologic tumor size did not differ significantly between the two groups (1.8 cm for high-risk vs 1.7 cm for average-risk patients; p = 0.44). The high-risk patients were more likely to have tumors with high nuclear grade (p \ 0.0001; 56 % grade 3 cases vs 27 % in the average-risk group) and less likely to have more than 2 mm of microscopic ECE than the average-risk patients (17 vs 24 %; p = 0.0497).
A median of four versus three SLNs were excised in the high-versus the average-risk group (p = 0.04), with a median of one positive SLN in both groups. The criteria for SLNB alone were met by 205 high-risk patients (85 %) and 377 average-risk patients (82 %) (p = 0.39). Among 37 high-risk patients (15 %) and 82 average-risk patients (18 %) who had ALND (p = 0.39), the indications were similar, with ALND performed for more than two positive SLNs in 70 % of the high-risk cases and 62 % of the averagerisk cases, and for gross ECE in 24 % of the high-risk cases and 30 % of the average-risk cases (p = 0.69) ( Table 2 ). The median number of additional nodes excised at ALND was 15 (range 4-52) in the high-risk group and 14 (range 0-53) in the average-risk group (p = 0.35) ( Table 2 ). Additional positive nodes were found in 62 % of the high-risk cases versus 65 % of the average-risk cases (p = 0.8), with a median of three additional positive nodes in both groups (Table 2 ). A total of 10 patients (5 high-risk and 5 averagerisk patients) did not undergo ALND despite having more than two positive SLNs (2 patients refused, 4 had significant medical comorbidities thought to preclude further surgery, and 4 were deferred per the surgeon's clinical judgment).
Adjuvant therapies and outcomes were assessed for patients undergoing SLNB alone who completed surgery in 2014 or before (n = 470: 166 high-risk and 304 averagerisk patients) to allow for a follow-up period of at least 12 months. Adjuvant chemotherapy was administered to 156 high-risk patients (95 %) versus 195 average-risk patients (64 %) (p \ 0.0001) and endocrine therapy to 116 (95 %) of the 122 high-risk patients and 291 (96 %) of the 302 average-risk patients who were hormone receptorpositive (p = 0.54). All the HER2? patients received HER2 targeted therapy. Systemic adjuvant therapy status was unknown for one high-risk patient and three averagerisk patients. Adjuvant radiotherapy was administered to 440 patients (94 %), including 161 high-risk patients (97 %) and 279 average-risk patients (92 %) (p = 0.03). Whole-breast irradiation was given to 422 patients (96 %), with 81 (18 %) patients undergoing additional nodal irradiation and 1 patient receiving intraoperative radiotherapy. Data regarding radiated fields were unavailable for 17 (4 %) of the cases. The use of nodal irradiation did not At this writing, after a median follow-up period of 34 months (high-risk group) versus 30 months (averagerisk group) (range 1-63 months), no isolated axillary recurrences have been experienced in either group. Two patients in each group have had in-breast recurrence only, and two patients in each group have had synchronous axillary and breast recurrences. Two patients in the highrisk group have had synchronous axillary and distant recurrence, and one patient has experienced synchronous breast and distant recurrence. Among the four high-risk patients with axillary recurrences, one was TN, two were younger than 50 years, and one was younger than 50 years with TN cancer. None were HER2?. No combined local/ distant recurrences have been experienced in the averagerisk group.
DISCUSSION
Our study provides evidence in a large consecutive cohort of T1-T2 cN0 patients prospectively treated during a 5-year period that younger patients and those with TN or HER2 overexpressing cancers are no more likely to require ALND due to the presence of three or more positive SLNs or gross ECE than those 50 years of age or older with ER?/HER2-breast cancer. A study from the National Cancer Database including 74,309 patients meeting the Z0011 eligibility criteria from 1998 to 2011 showed that the overall rates of SLNB alone for patients with nodepositive breast cancer markedly increased in the post-Z0011 era, rising from 6 % in 1998 to 56 % in 2011. However, among the subset of 9860 patients treated after Z0011, the independent predictors of ALND included TN receptor status (p \ 0.001) and age younger than 50 years (p = 0.006). 7 Our findings provide compelling evidence for a change in this approach, with only 15 % of high-risk patients in our study having indications for ALND.
Past studies of SLNB followed by ALND for metastases in one or two SLNs report a non-SLN metastases incidence of 27-46 %, 2, 4, 8, 9 increasing to as high as 70 % for patients with three or more positive SLNs. 10 These reported rates are from populations primarily consisting of hormone receptor-positive older women, who constitute the majority of breast cancer patients. In a retrospective study of 183 high-risk patients, also defined as HER2?, TN, or age younger than 50 years, 125 patients met the Z0011 clinical eligibility criteria (cT1-T2 cN0 with positive SLNs). Of these patients, 84 % underwent ALND, and only 38 % had non-SLN involvement, 11 supporting our findings that patient and tumor features associated with a higher risk of distant metastases are not indicative of a heavy axillary tumor burden. Although younger patients and those with hormone receptor-negative tumors are known to have tumors with a more aggressive biology and a poorer prognosis, [12] [13] [14] [15] among those with indications for ALND in our study, a similar residual nodal disease burden, with a median of three additional positive nodes, was present in both the high-and average-risk groups.
Multiple studies have demonstrated that patients with TN tumors are significantly less likely than those with other tumor subtypes to have metastases in four or more axillary nodes. 12, 13, 16, 17 In a study of 284 women meeting the Z0011 clinical eligibility criteria who underwent SLNB followed by ALND, not only was the likelihood of additional nonsentinel disease lowest among the TN cases (21 %), but all the cases had fewer than four nonsentinel nodes involved when additional metastases were present. 17 This study also found that age was not associated with the presence of four or more positive nodes (p = 0.6). 17 The literature on nodal involvement in patients with HER2? tumors suggests that these patients are more likely to have a heavier nodal burden. Gangi et al. 18 in a study of 2967 patients undergoing any breast surgery with either SLNB or ALND, found that 19 % of HER2? patients had metastases in four or more nodes, with the lowest rate (9 %; p \ 0.0001) among the TN cases. Multivariate analysis, after adjustment for size, grade, age, and presence of lymphovascular invasion, showed that HER2? subtypes were more likely to have four or more positive nodes (odds ratio [OR], 1.4; range 0.9-2.3), whereas the TN subtype was the least likely (OR 0.5; range 0.3-1.1; p = 0.008). Age younger than 50 years also was not predictive of a patient having four or more positive nodes.
Similarly, Wiechmann et al. 16 in a larger study investigating 6072 patients with stages 1-3 cancers, found that HER2? patients were significantly more likely to have involvement of four or more lymph nodes than those with hormone receptor-positive or TN cancers (p \ 0.0001) after controlling for age, tumor size, lymphovascular invasion, and grade. Although the possibility of a greater nodal disease burden in HER2? cases might raise concern about omission of ALND for patients with metastases in one or two SNs, this should be offset by the documented effectiveness of HER2 targeted therapy in combination with chemotherapy in eradicating nodal disease in the neoadjuvant setting. [19] [20] [21] This is supported by our finding that none of the axillary recurrences were experienced by HER2? patients. Along with having similar rates of ALND and equivalent nodal disease burden, the LRR rates also were comparable between the high-and average-risk patients in this study. Although the absence of any isolated axillary recurrences in our population with a median follow-up period of 2.6 years is reassuring, further follow-up study is necessary to determine the rate of regional failure in this group. However, the majority of recurrences in patients with HER2? and TN disease occur within the first 5 years after initial diagnosis, suggesting that rates of isolated axillary failure are unlikely to increase dramatically with further follow-up. [22] [23] [24] [25] [26] In this study, the majority of recurrences in the high-risk group included distant metastases (71 %). The study showed only four locoregional-only recurrences, and none were isolated axillary recurrences, emphasizing the importance of avoiding unnecessary surgical morbidity for these patients. 14, 27, 28 Although ongoing follow-up study will determine the long-term rates of regional recurrence, the results of this study support the application of the Z0011 results to patients otherwise meeting the study clinical eligibility criteria regardless of age or receptor status.
